SCHEMBL788798

SCHEMBL788798

c1cc(-c2nccnn2)nnn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL586397 0.82 TP53 (0.39)
SCHEMBL21315707 0.77 GABRA1 (0.35)
SCHEMBL31413695 0.77 KDM4E (0.37)
SCHEMBL25493617 0.76 TP53 (0.38)
SCHEMBL379708 0.75 KDM4E (0.32)
Charcoal, Activated SCHEMBL30558882 0.73 KDM4E (0.31)
SCHEMBL29522058 0.72
SCHEMBL5553224 0.72
SCHEMBL16741960 0.72 CCR1 (0.33)
SCHEMBL11349621 0.72 HSP90AA1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2591674-B1 Heterocyclic compounds as pest controllers BAYER CROPSCIENCE AG (DE) 2016-01-13 EP claimed
US-9221042-B2 Metal complexes, especially the ruthenium complexes, and use thereof APEIRON SYNTHESIS S.A. (PL) 2015-12-29 US claimed
CN-115703802-A Boron-containing organic compound and application thereof 北京鼎材科技有限公司 2023-02-17 CN disclosed
CN-115463219-A Pharmaceutical composition containing beta-lactam compound and application thereof 中国医学科学院医药生物技术研究所 2022-12-13 CN disclosed
CN-115244723-A Organic electroluminescent device 默克专利有限公司 2022-10-25 CN disclosed
US-10980835-B2 Arsenic trioxide for treatment of PIN1-associated disorders BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2021-04-20 US disclosed
WO-2020117867-A1 DARINAPARSIN AND RETINOIC ACID COMPOUNDS FOR TREATMENT OF IDH-ASSOCIATED DISORDERS BETH ISRAEL-DEACONESS MEDICAL CENTER, INC. (US) 2020-06-11 WO disclosed
WO-2020117868-A1 ARSENIC COMPOUNDS AND RETINOIC ACID COMPOUNDS FOR TREATMENT OF IDH-ASSOCIATED DISORDERS BETH ISRAEL-DEACONESS MEDICAL CENTER, INC. (US) 2020-06-11 WO disclosed
US-10548864-B2 Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2020-02-04 US disclosed
WO-2019182015-A1 ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND 持田製薬株式会社 2019-09-26 WO disclosed
US-10265288-B2 Methods and compositions for the treatment of proliferative disorders BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2019-04-23 US disclosed
US-9439884-B2 Methods for the treatment of immune disorders BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2016-09-13 US disclosed
US-20150044278-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2015-02-12 US disclosed
US-20140219957-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2014-08-07 US disclosed
CN-103702967-A Methods and compositions for treatment of proliferative disorders BETH ISRAEL HOSPITAL 2014-04-02 CN disclosed
US-20140086909-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2014-03-27 US disclosed
WO-2012162698-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2012-11-29 WO disclosed
WO-2012037258-A1 PROCESSES FOR PREPARING 1,2-SUBSTITUTED CYCLOPROPYL DERIVATIVES ABBOTT LABORATORIES (US) 2012-03-22 WO disclosed
EP-1533292-B1 DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC (JP) 2007-02-14 EP disclosed
US-20040266764-A1 Hydroxamic acid derivatives HANNAH DUNCAN ROBERT 2004-12-30 US disclosed